Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10454788 | 0.73 | EGLN3 (0.66) | EGLN3MAPK1LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL21404585 | 0.70 | CPB2 (0.34) | — | |
| SCHEMBL2144407 | 0.69 | MTNR1A (0.54) | MTNR1AMTNR1BEGLN3LMNASMN1; SMN2 | |
| SCHEMBL3038961 | 0.68 | ALDH1A1 (0.51) | MTNR1ASMN1; SMN2HTTKMT2A | |
| SCHEMBL21404446 | 0.68 | MTNR1A (0.34) | MTNR1AMTNR1BMAPK1SMN1; SMN2L3MBTL1 | |
| SCHEMBL17293996 | 0.67 | ADORA2A (0.62) | — | |
| SCHEMBL21404329 | 0.67 | ESR1 (0.39) | MTNR1ALMNASMN1; SMN2HTTKMT2A | |
| SCHEMBL21404375 | 0.67 | MEN1 (0.34) | MTNR1AMTNR1BSMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL2144935 | 0.66 | MTNR1A (0.45) | MTNR1AMTNR1BEGLN3KMT2ACASP1 | |
| SCHEMBL1397009 | 0.66 | MTNR1A (0.45) | MTNR1AMTNR1BEGLN3LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230008047-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-01-12 | — | — | US | disclosed |
| US-11058688-B2 | Imidazopiperazine inhibitors of transcription activating proteins | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3773587-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | Board of Regents, The University of Texas System (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019191667-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20190298729-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11058688-B2 | Imidazopiperazine inhibitors of transcription activating proteins | EP300, CREBBP, RBBP7 | CREBBP 2/4885MTNR1A 3287/4885MTNR1B 3544/4885 |
| US-20230008047-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | EP300, CREBBP, RBBP7 | CREBBP 2/4885MTNR1A 3287/4885MTNR1B 3544/4885 |
| US-20190298729-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | EP300, CREBBP, RBBP7 | CREBBP 2/4885MTNR1A 3287/4885MTNR1B 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.